BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 2019;21:i18-31. [PMID: 30649489 DOI: 10.1093/neuonc/noy136] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 30.5] [Reference Citation Analysis]
Number Citing Articles
1 Hua L, Ren L, Wu Q, Deng J, Chen J, Cheng H, Wang D, Chen H, Xie Q, Wakimoto H, Gong Y. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk. J Neurooncol 2022. [DOI: 10.1007/s11060-022-04169-3] [Reference Citation Analysis]
2 Di Nunno V, Giannini C, Asioli S, Conti A, Furtner J, Balestrini D, Tosoni A. Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3. Cancers 2022;14:4689. [DOI: 10.3390/cancers14194689] [Reference Citation Analysis]
3 Mederer T, Schachinger S, Rosengarth K, Brosig A, Schebesch K, Doenitz C, Schmidt N, Proescholdt MA. Symptom burden and surgical outcome in non-skull base meningiomas. Front Oncol 2022;12:967420. [DOI: 10.3389/fonc.2022.967420] [Reference Citation Analysis]
4 Young JS, Kidwell RL, Zheng A, Haddad AF, Aghi MK, Raleigh DR, Schulte JD, Butowski NA. CDK 4/6 inhibitors for the treatment of meningioma. Front Oncol 2022;12:931371. [DOI: 10.3389/fonc.2022.931371] [Reference Citation Analysis]
5 Behling F, Fodi C, Skardelly M, Paulsen F, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J. The prognostic role of the immunohistochemical expression of S100 in meningiomas. J Cancer Res Clin Oncol 2022. [PMID: 35838837 DOI: 10.1007/s00432-022-04186-9] [Reference Citation Analysis]
6 Takase H, Yamamoto T. Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives. Front Oncol 2022;12:895374. [DOI: 10.3389/fonc.2022.895374] [Reference Citation Analysis]
7 Vasudevan HN, Choudhury A, Hilz S, Villanueva-Meyer JE, Chen WC, Lucas CG, Braunstein SE, Oberheim Bush NA, Butowski N, Pekmezci M, McDermott MW, Perry A, Solomon DA, Magill ST, Raleigh DR. Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathol 2022. [PMID: 35759011 DOI: 10.1007/s00401-022-02455-y] [Reference Citation Analysis]
8 Horbinski C, Berger T, Packer RJ, Wen PY. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol 2022. [PMID: 35729337 DOI: 10.1038/s41582-022-00679-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Peng W, Wu P, Yuan M, Yuan B, Zhu L, Zhou J, Li Q. Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature. Front Oncol 2022;12:850463. [PMID: 35712491 DOI: 10.3389/fonc.2022.850463] [Reference Citation Analysis]
10 Palmisciano P, Watanabe G, Conching A, Ogasawara C, Ferini G, Bin-Alamer O, Haider AS, Sabini MG, Cuttone G, Cosentino S, Ippolito M, Umana GE. The Role of [68Ga]Ga-DOTA-SSTR PET Radiotracers in Brain Tumors: A Systematic Review of the Literature and Ongoing Clinical Trials. Cancers (Basel) 2022;14:2925. [PMID: 35740591 DOI: 10.3390/cancers14122925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Perveen R, Naveed Babur M, Shah NUA, Hafeez A, Sabir S, Fatima T, Shahzad Ali R, Faizan A. Emerging trends in Diagnosis and Treatment of Brain Tumor. PBMJ 2022. [DOI: 10.54393/pbmj.v5i5.478] [Reference Citation Analysis]
12 Kent CL, Mowery YM, Babatunde O, Wright AO, Barak I, Mcsherry F, Herndon JE, Friedman AH, Zomorodi A, Peters K, Desjardins A, Friedman H, Sperduto W, Kirkpatrick JP. Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience. Advances in Radiation Oncology 2022;7:100878. [DOI: 10.1016/j.adro.2021.100878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lessa SS, Chang Mulato JE, Dória-netto HL, Wuo-silva R, Filho JMC, Chaddad-neto F. Microsurgery for a medial left giant lesser sphenoid wing meningioma complicated by postoperative vasospasm of the ipsilateral supraclinoid carotid artery. Surgical Neurology International 2022;13:113. [DOI: 10.25259/sni_90_2022] [Reference Citation Analysis]
14 Yamamoto M, Suzuki S, Togashi K, Sugai A, Okada M, Kitanaka C. Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Cancers 2022;14:1706. [DOI: 10.3390/cancers14071706] [Reference Citation Analysis]
15 Arora M, Kutinová Canová N, Farghali H. mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ammendola S, Simbolo M, Ciaparrone C, Rizzo PC, Caffo M, Pinna G, Sala F, Scarpa A, Barresi V. Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series. Current Oncology 2022;29:178-85. [DOI: 10.3390/curroncol29010017] [Reference Citation Analysis]
17 Holzgreve A, Unterrainer M, Suchorska B, Albert NL. Case 27: Meningioma with Difficult Delineation on MRI. Clinical Nuclear Medicine in Neurology 2022. [DOI: 10.1007/978-3-030-83598-9_27] [Reference Citation Analysis]
18 Gadot R, Khan AB, Patel R, Goethe E, Shetty A, Hadley CC, V JCB, Harmanci AS, Klisch TJ, Yoshor D, Sheth SA, Patel AJ. Predictors of postoperative seizure outcome in supratentorial meningioma. J Neurosurg 2021;:1-10. [PMID: 35099915 DOI: 10.3171/2021.9.JNS211738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Nakano T, Fujimoto K, Tomiyama A, Takahashi M, Achiha T, Arita H, Kawauchi D, Yasukawa M, Masutomi K, Kondo A, Narita Y, Maehara T, Ichimura K. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma. Cancer Sci 2021. [PMID: 34839570 DOI: 10.1111/cas.15221] [Reference Citation Analysis]
20 Nassiri F, Wang JZ, Au K, Barnholtz-Sloan J, Jenkinson MD, Drummond K, Zhou Y, Snyder JM, Brastianos P, Santarius T, Suppiah S, Poisson L, Gaillard F, Rosenthal M, Kaufmann T, Tsang D, Aldape K, Zadeh G. Consensus core clinical data elements for meningiomas. Neuro Oncol 2021:noab259. [PMID: 34791428 DOI: 10.1093/neuonc/noab259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Tollefsen SE, Jarmund AH, Ytterhus B, Salvesen Ø, Mjønes P, Torp SH. Somatostatin Receptors in Human Meningiomas-Clinicopathological Aspects. Cancers (Basel) 2021;13:5704. [PMID: 34830858 DOI: 10.3390/cancers13225704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Yamamoto M, Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Sato A, Okada M, Kitanaka C. Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax. Neurooncol Adv 2021;3:vdab148. [PMID: 34765973 DOI: 10.1093/noajnl/vdab148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Roesler R, Souza BK, Isolan GR. Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. Int J Mol Sci 2021;22:11352. [PMID: 34768783 DOI: 10.3390/ijms222111352] [Reference Citation Analysis]
24 Feraco P, Scartoni D, Porretti G, Pertile R, Donner D, Picori L, Amelio D. Predict Treatment Response by Magnetic Resonance Diffusion Weighted Imaging: A Preliminary Study on 46 Meningiomas Treated with Proton-Therapy. Diagnostics (Basel) 2021;11:1684. [PMID: 34574025 DOI: 10.3390/diagnostics11091684] [Reference Citation Analysis]
25 Mastronardi L, Campione A, Cacciotti G, Carpineta E, Scavo CG, Roperto R, Stati G, Sufianov AA, Schaller K. Microsurgical treatment of symptomatic vestibular schwannomas in patients under 40: different results before and after age of 30. Neurosurg Rev 2021. [PMID: 34405315 DOI: 10.1007/s10143-021-01603-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M, Schittenhelm J, Tabatabai G; International Consortium on Meningiomas. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol 2021;23:1273-81. [PMID: 33367841 DOI: 10.1093/neuonc/noaa303] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
27 Magge RS, Barbaro M, Fine HA. Innovations in Neuro-Oncology. World Neurosurg 2021;151:386-91. [PMID: 34243672 DOI: 10.1016/j.wneu.2021.02.093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lv P, Wang JJ, Xiong NX, Liu XM, Yao DX, Jiang XB, Zhao HY, Zhang FC, Fu P. Long-term outcome in meningiomas involving the major dural sinuses with combined therapy of subtotal resection and early postoperative gamma knife radiosurgery. Acta Neurochir (Wien) 2021;163:1677-85. [PMID: 33608765 DOI: 10.1007/s00701-021-04766-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J. Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev 2021. [PMID: 33899156 DOI: 10.1007/s10143-021-01552-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
30 Susko MS, Chen WC, Vasudevan HN, Magill ST, Lucas CG, Oberheim Bush NA, Solomon DA, Theodosopoulos PV, McDermott MW, Villanueva-Meyer JE, Boreta L, Nakamura JL, Sneed PK, Braunstein SE, Raleigh DR. Letter: Patterns of Intermediate- and High-Risk Meningioma Recurrence After Treatment With Postoperative External Beam Radiotherapy. Neurosurgery 2021;89:E99-E101. [PMID: 33887769 DOI: 10.1093/neuros/nyab143] [Reference Citation Analysis]
31 Zamanipoor Najafabadi AH, van der Meer PB, Boele FW, Taphoorn MJB, Klein M, Peerdeman SM, van Furth WR, Dirven L; Dutch Meningioma Consortium. Long-Term Disease Burden and Survivorship Issues After Surgery and Radiotherapy of Intracranial Meningioma Patients. Neurosurgery 2020;88:155-64. [PMID: 32818258 DOI: 10.1093/neuros/nyaa351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Jungwirth G, Yu T, Cao J, Eddine MA, Moustafa M, Warta R, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Lett 2021;506:1-10. [PMID: 33652084 DOI: 10.1016/j.canlet.2021.02.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
33 Franconeri A, Sacco S, Raciti MV, Maggi A, Muzic SI, Imparato S, Farina L, Bacila A, Paganelli C, Buizza G, Fontana G, Baroni G, Riva G, Iannalfi A, Orlandi E, Preda L. Intravoxel incoherent motion as a tool to detect early microstructural changes in meningiomas treated with proton therapy. Neuroradiology 2021;63:1053-60. [PMID: 33392736 DOI: 10.1007/s00234-020-02630-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Akutsu H, Matsuda M, Ishikawa T. Current Status and Future Perspectives on Surgical and Non-Surgical Treatments for WHO Grade Ⅱ and Ⅲ Meningioma. Jpn J Neurosurg 2021;30:356-364. [DOI: 10.7887/jcns.30.356] [Reference Citation Analysis]
35 Franke JL, Jackson C, Lim M. Approach to the meningioma patient. Neuro-Oncology for the Clinical Neurologist 2021. [DOI: 10.1016/b978-0-323-69494-0.00010-5] [Reference Citation Analysis]
36 Weber DC, Bizzocchi N, Bolsi A, Jenkinson MD. Proton Therapy for Intracranial Meningioma for the Treatment of Primary/Recurrent Disease Including Re-Irradiation. Front Oncol 2020;10:558845. [PMID: 33381447 DOI: 10.3389/fonc.2020.558845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Combs SE, Baumert BG, Bendszus M, Bozzao A, Brada M, Fariselli L, Fiorentino A, Ganswindt U, Grosu AL, Lagerwaard FL, Niyazi M, Nyholm T, Paddick I, Weber DC, Belka C, Minniti G. ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother Oncol 2021;156:80-94. [PMID: 33309848 DOI: 10.1016/j.radonc.2020.11.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
38 Ota HCU, Smith BG, Alamri A, Robertson FC, Marcus H, Hirst A, Broekman M, Hutchinson P, McCulloch P, Kolias A. The IDEAL framework in neurosurgery: a bibliometric analysis. Acta Neurochir (Wien) 2020;162:2939-47. [PMID: 32651707 DOI: 10.1007/s00701-020-04477-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Fountain DM, Smith MJ, O'Leary C, Pathmanaban ON, Roncaroli F, Bobola N, King AT, Evans DG. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene 2021;40:875-84. [PMID: 33262459 DOI: 10.1038/s41388-020-01568-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Seo K, Lucas CG, Villanueva-meyer JE, Lam T, Pu JK, Li L, Leung GK, Vasudevan HN, Liu SJ, Chan JW, Qiu Z, Zhang MY, Martin MV, Susko MS, Braunstein SE, Oberheim Bush NA, Schulte J, Butowski N, Sneed PK, Berger MS, Perry A, Phillips JJ, Solomon DA, Costello JF, Mcdermott MW, Rich JN, Raleigh DR. Meningioma epigenetic grouping reveals biologic drivers and therapeutic vulnerabilities.. [DOI: 10.1101/2020.11.23.20237495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Sauvigny T, Ricklefs FL, Hoffmann L, Schwarz R, Westphal M, Schmidt NO. Features of tumor texture influence surgery and outcome in intracranial meningioma. Neurooncol Adv 2020;2:vdaa113. [PMID: 33134922 DOI: 10.1093/noajnl/vdaa113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Behling F, Fodi C, Hoffmann E, Renovanz M, Skardelly M, Tabatabai G, Schittenhelm J, Honegger J, Tatagiba M. The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. Neurosurg Rev 2021;44:2329-36. [PMID: 33104905 DOI: 10.1007/s10143-020-01428-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
43 Huntoon K, Toland AMS, Dahiya S. Meningioma: A Review of Clinicopathological and Molecular Aspects. Front Oncol 2020;10:579599. [PMID: 33194703 DOI: 10.3389/fonc.2020.579599] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
44 Garzon-Muvdi T, Bailey DD, Pernik MN, Pan E. Basis for Immunotherapy for Treatment of Meningiomas. Front Neurol 2020;11:945. [PMID: 32982948 DOI: 10.3389/fneur.2020.00945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
45 Magill ST, Vasudevan HN, Seo K, Villanueva-Meyer JE, Choudhury A, John Liu S, Pekmezci M, Findakly S, Hilz S, Lastella S, Demaree B, Braunstein SE, Bush NAO, Aghi MK, Theodosopoulos PV, Sneed PK, Abate AR, Berger MS, McDermott MW, Lim DA, Ullian EM, Costello JF, Raleigh DR. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun 2020;11:4803. [PMID: 32968068 DOI: 10.1038/s41467-020-18582-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
46 Haddad AF, Young JS, Kanungo I, Sudhir S, Chen JS, Raleigh DR, Magill ST, McDermott MW, Aghi MK. WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index. Front Oncol 2020;10:1522. [PMID: 32983999 DOI: 10.3389/fonc.2020.01522] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
47 Zhao L, Zhao W, Hou Y, Wen C, Wang J, Wu P, Guo Z. An Overview of Managements in Meningiomas. Front Oncol 2020;10:1523. [PMID: 32974188 DOI: 10.3389/fonc.2020.01523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
48 Findakly S, Choudhury A, Daggubati V, Pekmezci M, Lang UE, Raleigh DR. Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals. Acta Neuropathol Commun 2020;8:114. [PMID: 32690089 DOI: 10.1186/s40478-020-00994-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Sarhan N, Abduljabbar L, Laperriere N, Shultz D, Asha M, Zadeh G, Millar BA, Tsang DS. Short Course Hypofractionated Radiotherapy for Frail or Elderly Patients With Meningioma. Cureus 2020;12:e8604. [PMID: 32676243 DOI: 10.7759/cureus.8604] [Reference Citation Analysis]
50 Omer S, Murat B, Ferrat D, Selcuk D, Hakan G, Bora U, Onurhan C, Fatih O, Bahar D. Multimodality management of cavernous sinus meningiomas with less extensive surgery followed by subsequent irradiation: Implications for an improved toxicity profile. J Surg Surgical Res 2020;6:056-061. [DOI: 10.17352/2455-2968.000098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Nakahara Y, Ito H, Masuoka J, Abe T. Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas. Cancers (Basel) 2020;12:E1334. [PMID: 32456178 DOI: 10.3390/cancers12051334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
52 Adams CL, Ercolano E, Ferluga S, Sofela A, Dave F, Negroni C, Kurian KM, Hilton DA, Hanemann CO. A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours. Int J Mol Sci 2020;21:E1273. [PMID: 32070062 DOI: 10.3390/ijms21041273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
53 Roque AM, Omuro A. The Role of Medical Therapy for Menigniomas. Meningiomas 2020. [DOI: 10.1007/978-3-030-59558-6_13] [Reference Citation Analysis]
54 Yoshimoto K. Genomic Analysis and Gene-based Medicine for Benign Brain Tumors. Jpn J Neurosurg 2020;29:536-542. [DOI: 10.7887/jcns.29.536] [Reference Citation Analysis]
55 Mooney MA, Bi WL, Cantalino JM, Wu KC, Harris TC, Possatti LL, Juvekar P, Hsu L, Dunn IF, Al-Mefty O, Devlin PM. Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study. J Neurooncol 2020;146:111-20. [PMID: 31745706 DOI: 10.1007/s11060-019-03342-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Unterrainer M, Niyazi M, Tonn JC, Ilhan H, Bartenstein P, Albert NL. A look ahead: future directions of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 2019;7:357-62. [DOI: 10.1007/s40336-019-00333-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Loewenstern J, Rutland J, Gill C, Arib H, Pain M, Umphlett M, Kinoshita Y, McBride R, Donovan M, Sebra R, Bederson J, Fowkes M, Shrivastava R. Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. Oncotarget 2019;10:3506-17. [PMID: 31191822 DOI: 10.18632/oncotarget.26941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]